Form 8-K

8-K — Alpha Teknova, Inc.

Accession: 0001850902-26-000007

Filed: 2026-05-06

Period: 2026-05-04

CIK: 0001850902

SIC: 2835 (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES)

Item: Results of Operations and Financial Condition

Item: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics

Item: Financial Statements and Exhibits

Documents

8-K — tkno-20260504.htm (Primary)

EX-99.1 (tkno-ex99_1.htm)

GRAPHIC (img201297901_0.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: tkno-20260504.htm · Sequence: 1

8-K

0001850902false00018509022026-05-042026-05-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 04, 2026

Alpha Teknova, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-40538

94-3368109

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

2451 Bert Drive

Hollister, California

95023

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 831 637-1100

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.00001 per share

TKNO

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 6, 2026, Alpha Teknova, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026 (the “Press Release”). A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the Press Release, is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 5.05 Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics.

On May 4, 2026, the Board of Directors of the Company approved an amended and restated Code of Business Conduct and Ethics (the “Code”). The Code was amended to, among other things, update for current compliance best practices, streamline and clarify existing provisions, promote consistency in cross-reference to other of the Company’s polices, and to make other non-substantive administrative and stylistic improvements. The amendments do not constitute, or result in, a waiver of any provision of the Code as previously in effect.

The foregoing description of the amendments to the Code does not purport to be complete and is qualified in its entirety by reference to the full text of the Code, which available on the “Investor Relations – Corporate Governance” section of the Company’s website at www.teknova.com.The contents of the Company’s website are not incorporated by reference in this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release issued by Alpha Teknova, Inc., dated May 6, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALPHA TEKNOVA, INC.

Date:

May 6, 2026

By:

/s/ Stephen Gunstream

Stephen Gunstream

President and Chief Executive Officer

EX-99.1

Filename: tkno-ex99_1.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Teknova Reports First Quarter 2026 Financial Results

First quarter 2026 total revenue was $11.1 million, up 13% over the same quarter prior year

Company reaffirms 2026 revenue guidance of $42-44 million

HOLLISTER, Calif., May 6, 2026 – Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2026.

“We had a great start to 2026,” said Stephen Gunstream, President and Chief Executive Officer at Teknova. “The substantial investments we’ve made since 2021, combined with an improved market backdrop, position Teknova for sustainable above-market growth over the next couple years, particularly as our Clinical Solutions customers advance their therapies and diagnostics towards commercialization.”

Matt Lowell, Teknova’s Chief Financial Officer, added, “We delivered strong financial results in the first quarter 2026 compared to 2025, including 13% revenue growth and significant improvements in Adjusted EBITDA and Free Cash Outflow. We believe the Company is well positioned to maintain its momentum. We therefore reiterate our 2026 revenue guidance of $42-44 million and continue to anticipate full-year Free Cash Outflow of less than $10 million,” he explained.

Corporate and Financial Updates

•

First quarter 2026 total revenue of $11.1 million, up 13% compared to $9.8 million for the first quarter 2025

•

Total cash and short-term investments were $17.8 million and total borrowings were $13.2 million at the end of the first quarter 2026

Revenue for the First Quarter 2026

For the Three Months Ended

March 31,

(Dollars in thousands)

2026

2025

Lab Essentials

8,395

8,117

Clinical Solutions

2,145

1,162

Other

537

516

Total revenue

11,077

9,795

First Quarter 2026 Financial Results

Total revenue for the first quarter 2026 was $11.1 million, up 13% compared to $9.8 million in the first quarter 2025. Lab Essentials revenue was $8.4 million in the first quarter 2026, up 3% compared to $8.1 million in the first quarter 2025. Clinical Solutions revenue was $2.1 million in the first quarter 2026, up 85% compared to $1.2 million in the first quarter 2025.

Gross profit for the first quarter 2026 was $3.8 million, compared to $3.0 million in the first quarter 2025. Gross margin for the first quarter 2026 was 34.2%, compared to 30.7% in the first quarter 2025. The increase in gross margin was primarily driven by higher revenue.

Operating expenses for the first quarter 2026 were $8.1 million, compared to $8.0 million in the first quarter 2025. The increase was primarily driven by higher spending in sales and marketing, resulting from higher headcount and increased marketing expenses, partially offset by lower general and administrative expenses attributable to lower stock-based compensation expense and professional fees.

Net loss for the first quarter 2026 was $4.6 million, or negative $0.08 per diluted share, compared to $4.6 million, or negative $0.09 per diluted share, for the first quarter 2025. Adjusted EBITDA for the first quarter 2026 was negative $2.0 million, compared to negative $2.5 million for the first quarter 2025.

Cash used in operating activities for the first quarter 2026 was $3.4 million, compared to $4.1 million of cash used in operating activities for the first quarter 2025. Free Cash Outflow was $3.6 million for the first quarter 2026, compared to $4.3 million for the first quarter 2025.

A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.

Reaffirms 2026 Outlook

Teknova reaffirms its fiscal 2026 outlook for revenue and Free Cash Outflow. The Company continues to anticipate total revenue of $42 million to $44 million for the fiscal year ending December 31, 2026 (“2026”). The Company also anticipates Free Cash Outflow of less than $10 million for 2026.

Upcoming Investor Conference Attendance

Craig-Hallum Institutional Investor Conference (Minneapolis, MN)

Thursday, May 28, 2026

William Blair Growth Stock Conference (Chicago, IL)

Thursday, June 4, 2026

Conference Call and Webcast

Teknova will host a webcast and conference call on Wednesday, May 6, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Teknova

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic

modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.

Non-GAAP Financial Measures

This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of its business and the effectiveness of its business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow (Outflow).

Teknova defines Adjusted EBITDA as net income (loss) adjusted for interest income (expense), net, provision for (benefit from) income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representative of its ongoing operating performance.

Teknova defines Free Cash Flow (Outflow) as cash provided by (used in) operating activities less purchases of property, plant, and equipment.

Teknova provides Adjusted EBITDA and Free Cash Flow (Outflow) in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova’s industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova’s operating results because they exclude items that are not indicative of Teknova’s core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.

A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to Teknova’s anticipated total revenue, including our expectations for 2026 revenue and Free Cash Outflow guidance, and other statements about Teknova’s business prospects, including about Teknova’s profitability, strategy of managing operating expenses, and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results

to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, demand for Teknova’s products (including the potential delay to or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the conflicts in Ukraine and the Middle East; potential acquisitions and integration of other companies; and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which Teknova makes only as of the date hereof, even if they are repeated by Teknova subsequently. Teknova does not intend and shall have no obligation to update, amend, or clarify these forward-looking statements, except as may be required under applicable securities laws.

Investor Contact

Matt Lowell

Chief Financial Officer

matt.lowell@teknova.com

+1 831-637-1100

Media Contact

Jennifer Henry

Senior Vice President, Marketing

jenn.henry@teknova.com

+1 831-313-1259

ALPHA TEKNOVA, INC.

Condensed Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

For the Three Months Ended

March 31,

2026

2025

Revenue

11,077

9,795

Cost of sales

7,293

6,788

Gross profit

3,784

3,007

Operating expenses:

Research and development

609

552

Sales and marketing

2,128

1,640

General and administrative

5,058

5,492

Amortization of intangible assets

287

Total operating expenses

8,082

7,971

Loss from operations

(4,298

)

(4,964

)

Other (expenses) income, net

Interest expense, net

(219

)

(144

)

Other adjustment to loan exit fee

—

485

Other income

—

Total other (expenses) income, net

(210

)

341

Loss before income taxes

(4,508

)

(4,623

)

Provision for income taxes

Net loss

(4,555

)

(4,645

)

Net loss per share—basic and diluted

(0.08

)

(0.09

)

Weighted average shares used in computing net loss per share—basic and diluted

53,606,278

53,421,533

ALPHA TEKNOVA, INC.

Condensed Balance Sheets

(Unaudited)

(In thousands)

As of March 31,

As of December 31,

2026

2025

ASSETS

Current assets:

Cash and cash equivalents

4,306

5,912

Short-term investments, held -to-maturity

13,478

15,426

Accounts receivable, net

5,672

4,618

Inventories, net

6,874

7,054

Prepaid expenses and other current assets

1,344

1,501

Total current assets

31,674

34,511

Property, plant, and equipment, net

40,524

41,733

Operating right-of-use lease assets

13,608

14,112

Intangible assets, net

11,656

11,943

Other non-current assets

1,195

1,285

Total assets

98,657

103,584

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

1,618

1,378

Accrued liabilities

3,363

4,283

Current portion of operating lease liabilities

1,915

1,876

Total current liabilities

6,896

7,537

Deferred tax liabilities

925

879

Long-term debt, net

13,170

13,123

Long-term operating lease liabilities

12,742

13,270

Total liabilities

33,733

34,809

Stockholders’ equity:

Preferred stock

—

Common stock

Additional paid-in capital

205,268

204,564

Accumulated deficit

(140,345

)

(135,790

)

Total stockholders’ equity

64,924

68,775

Total liabilities and stockholders’ equity

98,657

103,584

ALPHA TEKNOVA, INC.

Condensed Statements of Cash Flows

(Unaudited)

(In thousands)

For the Three Months Ended

March 31,

2026

2025

Operating activities:

Net loss

(4,555

)

(4,645

)

Adjustments to reconcile net loss to net cash used in operating activities:

Bad debt expense

Inventory reserve

413

437

Depreciation and amortization

1,576

1,580

Stock-based compensation

695

852

Deferred taxes

Accrued interest income on short-term investments

(27

)

(54

)

Amortization of discount on short-term investments

(87

)

(184

)

Amortization of debt financing costs

Other adjustment to loan exit fee

—

(485

)

Non-cash lease expense

Changes in operating assets and liabilities:

Accounts receivable

(1,061

)

(1,349

)

Inventories

(233

)

(209

)

Prepaid expenses and other current assets

157

)

Other non-current assets

Accounts payable

330

740

Accrued liabilities

(772

)

(1,017

)

Other

—

(10

)

Cash used in operating activities

(3,359

)

(4,103

)

Investing activities:

Purchases of short-term investments

(3,938

)

(1,970

)

Maturities of short-term investments

6,000

Purchases of property, plant, and equipment

(221

)

(206

)

Cash provided by investing activities

1,841

3,824

Financing activities:

Proceeds from long-term debt

—

1,110

Payment of exit fee costs

—

(1,110

)

Repayment of financed insurance premiums

(97

)

(56

)

Proceeds from exercise of stock options

Cash used in financing activities

(88

)

(52

)

Change in cash and cash equivalents

(1,606

)

(331

)

Cash and cash equivalents at beginning of period

5,912

3,708

Cash and cash equivalents at end of period

4,306

3,377

ALPHA TEKNOVA, INC.

Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures

(Unaudited)

(In thousands)

For the Three Months Ended

March 31,

2026

2025

Net loss – as reported

(4,555

)

(4,645

)

Add back:

Interest expense, net

(219

)

(144

)

Provision for income taxes

Depreciation expense

1,289

1,293

Amortization of intangible assets

287

EBITDA

(2,713

)

(2,899

)

Other and non-recurring expenses:

Stock-based compensation expense

695

852

Other adjustment to loan exit fee

—

(485

)

Adjusted EBITDA

(2,018

)

(2,532

)

For the Three Months Ended

March 31,

2026

2025

Cash used in operating activities

(3,359

)

(4,103

)

Purchases of property, plant, and equipment

(221

)

(206

)

Free Cash Flow

(3,580

)

(4,309

)

GRAPHIC

Filename: img201297901_0.jpg · Sequence: 3

Binary file (375444 bytes)

Download img201297901_0.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Document And Entity Information

May 04, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 04, 2026

Entity Registrant Name

Alpha Teknova, Inc.

Entity Central Index Key

0001850902

Entity Emerging Growth Company

true

Entity File Number

001-40538

Entity Incorporation, State or Country Code

Entity Tax Identification Number

94-3368109

Entity Address, Address Line One

2451 Bert Drive

Entity Address, City or Town

Hollister

Entity Address, State or Province

Entity Address, Postal Zip Code

95023

City Area Code

831

Local Phone Number

637-1100

Entity Information, Former Legal or Registered Name

N/A

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Ex Transition Period

false

Title of 12(b) Security

Common Stock, par value $0.00001 per share

Trading Symbol

TKNO

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Former Legal or Registered Name of an entity

+ References

No definition available.

+ Details

Name:

dei_EntityInformationFormerLegalOrRegisteredName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration